The latest advancements are intended to address the requirements of trial sponsors and contract research organisations (CROs) seeking configurable, quickly deployable eCOA solutions that can function across any kind of device from a single study build.
These updates support modern clinical trial designs and the conduct of decentralised trials.
The drag-and-drop design tool used by the SmartSignals eCOA outputs consumer-grade user interfaces that adjust for any device automatically, expediting the trial design process by 40%-60%.
This software also simplifies the verification process, facilitating the study teams to effortlessly view their eCOA study design and confirm its alignment with a protocol’s schedule of activities or events tables.
SmartSignals eCOA also has an in-built, complete eCOA library that offers pre-validated, reusable scales available promptly on any device and comprises streamlined language version management.
Along with these back-end improvements that help study teams, the software offers trial subjects with simple interfaces that make it easier to collect data on patient-reported outcomes.
Furthermore, the built-in engagement features comprise access to trial and treatment information, latest visit schedules, secure video visits and study notifications that direct patients all through the trial.
The latest eCOA design tools, utilities and features of the company are offered as a standalone solution or along with other crucial digital trial options such as eConsent and telemedicine.
Signant Health chief product officer Sanjiv Waghmare said: “With our new eCOA design tools and utilities, we can maintain the same standards of data quality and integrity for which we are known while accelerating the study build process and reducing burdens on study teams.
“Importantly, our customers, sites and patients guided, piloted, and approved these design innovations.”
In May this year, the company introduced Oncology Complete offering that features complete clinical technology for streamlining modern oncology trials.